News from neurosigma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 30, 2017, 07:00 ET UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD

NeuroSigma, Inc. (NeuroSigma) today announced that on Friday, October 27, 2017, at the Annual Meeting of the American Academy of Child and Adolescent ...


Jan 06, 2015, 07:00 ET FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration ...


Jan 05, 2015, 07:00 ET UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

NeuroSigma®, Inc. (NeuroSigma) today announced that enrollment has commenced for a 90-subject Phase II pediatric clinical trial of its external...


Nov 19, 2014, 07:00 ET NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive external trigeminal nerve...


Oct 21, 2014, 07:00 ET NeuroSigma Receives Notice of Allowance of U.S. Patent Application

LOS ANGELES, Oct. 21, 2014 /PRNewswire/ – NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of...


Jul 22, 2014, 07:00 ET Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ Therapy for...


Mar 28, 2014, 07:00 ET NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...


Jan 21, 2014, 05:00 ET External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, today announced that two presentations were made last month at the annual...


Dec 05, 2013, 07:00 ET NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued ...


Jun 06, 2013, 07:00 ET NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression

NeuroSigma, Inc., a California-based medical device company, today announced the launch of www.monarch-etns.com, its dedicated website for the...


May 20, 2013, 05:00 ET Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)

Today, at the American Psychiatric Association (APA) Meeting in San Francisco, James McGough, M.D., M.S., principal investigator and Professor of...


Jan 22, 2013, 07:00 ET NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders

NeuroSigma, Inc., a California -based medical device company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice...


Sep 06, 2012, 03:01 ET NeuroSigma erhält CE-Kennzeichnung

NeuroSigma, Inc., ein in Los Angeles ansässiges medizinisches Technologieunternehmen gab heute bekannt, dass es die CE-Kennzeichnung für sein...


Sep 05, 2012, 06:56 ET NeuroSigma reçoit la certification CE

NeuroSigma, Inc., une entreprise de matériel médical basée à Los Angeles, a annoncé aujourd'hui avoir reçu la certification CE pour son système eTNS™ ...


Sep 05, 2012, 04:00 ET NeuroSigma Receives CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve...


Sep 06, 2011, 07:00 ET NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology...


Apr 28, 2011, 08:07 ET Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™

This afternoon, at the Antiepileptic Drug Trials XI Conference in Miami, Florida, (http://www.epilepsy.com/etp/aedtrialxi) Dr. Christopher DeGiorgio, ...